Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Will These 3 Products Revolutionize Diabetes Treatment?
Motley Fool
Sunday, June 15, 2014 - 6:58pm
tags:
diabetes, MannKind, Afrezza, Novo Nordisk, Apple
GSK spin-off gears up for possible listing
FT.com
Sunday, June 15, 2014 - 6:51pm
tags:
GSK, Convergence Pharmaceuticals, trigeminal neuralgia
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
Seeking Alpha
Sunday, June 15, 2014 - 6:31pm
tags:
InterMune, Esbriet, Actelion, Gilead Sciences
Novo Nordisk diabetes drug appears effective for weight loss -study
Yahoo/Reuters
Sunday, June 15, 2014 - 10:44am
tags:
Novo Nordisk, obesity, diabetes, Victoza
Medtronic Said to Be Looking to Cut Taxes With $40 Billion Covidien Deal
Yahoo/Bloomberg
Sunday, June 15, 2014 - 10:42am
tags:
M&A, Medtronic, Covidien, devices
Is Pfizer At A Saturation Point?
Seeking Alpha
Sunday, June 15, 2014 - 10:35am
tags:
Pfizer
New rivals to top diabetes drug Lantus show promise in studies
Yahoo/Reuters
Sunday, June 15, 2014 - 10:33am
tags:
diabetes, Lantus, insulin, Sanofi, Toujeo, Eli Lilly
Sanofi and Medtronic team up on diabetes drug-device combination
Yahoo/Reuters
Sunday, June 15, 2014 - 10:06am
tags:
Medtronic, Sanofi, diabetes, devices
Affymax and Takeda Announce Termination of Omontys (peginesatide) Product Collaboration and License Agreement
Pipeline Review
Saturday, June 14, 2014 - 9:51am
tags:
Takeda, Affymax, Omontys, anemia
Bayer faces law suits in United States over Xarelto -paper
Yahoo/Reuters
Saturday, June 14, 2014 - 9:34am
tags:
Bayer
Why Did Merck Spend $4 Billion on a Tiny Biotech Firm?
Wall St Cheat Sheet
Saturday, June 14, 2014 - 9:33am
tags:
Merck, Idenix
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA
Yahoo/BusinessWire
Saturday, June 14, 2014 - 9:29am
tags:
acute myeloid leukemia, leukemia, Vidaza, Celgene
New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies
Yahoo/BusinessWire
Saturday, June 14, 2014 - 9:27am
tags:
hematologic cancers, Agios Pharmaceuticals, AG-221
Is It Time to Buy Geron?
Motley Fool
Saturday, June 14, 2014 - 9:23am
tags:
Geron
Vantictumab Placed on Partial Clinical Hold by FDA Following Voluntary Halt by OncoMed
Yahoo/Globe Newswire
Saturday, June 14, 2014 - 9:22am
tags:
vantictumab, OncoMed
Is It Time to Buy Orexigen?
Motley Fool
Saturday, June 14, 2014 - 9:20am
tags:
Orexigen
AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal
Yahoo/Zacks
Saturday, June 14, 2014 - 9:18am
tags:
AstraZeneca, Synairgen, SNG001
Should Pfizer Buy Eli Lilly?
Motley Fool
Friday, June 13, 2014 - 6:52pm
tags:
Pfizer, Eli Lilly, M&A, AstraZeneca
Vivus hits Actavis with Qsymia patent-infringement lawsuit
Fierce Pharma
Friday, June 13, 2014 - 6:46pm
tags:
patents, Vivus, Qsymia, Actavis, generics
Enanta notes AbbVie granted FDA priority review for Hep C combo regimen
Yahoo/Fly on the Wall
Friday, June 13, 2014 - 6:44pm
tags:
AbbVie, Enanta Pharmaceuticals, FDA, hepatitis C, ABT-450

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.